Is Checkpoint Therapeutics Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: CKPT) stock is to Strong Buy CKPT stock.
Out of 2 analysts, 1 (50%) are recommending CKPT as a Strong Buy, 1 (50%) are recommending CKPT as a Buy, 0 (0%) are recommending CKPT as a Hold, 0 (0%) are recommending CKPT as a Sell, and 0 (0%) are recommending CKPT as a Strong Sell.
What is CKPT's revenue growth forecast for 2024-2024?
(NASDAQ: CKPT) Checkpoint Therapeutics's forecast annual revenue growth rate of 1,651% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Checkpoint Therapeutics's revenue in 2024 is $68,000.
In 2024, CKPT is forecast to generate $43,114,826 in revenue, with the lowest revenue forecast at $43,114,826 and the highest revenue forecast at $43,114,826.
What is CKPT's forecast return on assets (ROA) for 2024-2027?
(NASDAQ: CKPT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.
What is CKPT's Price Target?
According to 2 Wall Street analysts that have issued a 1 year CKPT price target, the average CKPT price target is $19.00, with the highest CKPT stock price forecast at $34.00 and the lowest CKPT stock price forecast at $4.00.
On average, Wall Street analysts predict that Checkpoint Therapeutics's share price could reach $19.00 by May 16, 2025. The average Checkpoint Therapeutics stock price prediction forecasts a potential upside of 910.64% from the current CKPT share price of $1.88.
What is CKPT's forecast return on equity (ROE) for 2024-2027?
(NASDAQ: CKPT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.